ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
27.83
+0.09 (0.32%)
At close: Sep 11, 2026, 4:00 PM EDT
27.55
-0.28 (-1.01%)
After-hours: Sep 11, 2026, 7:34 PM EDT
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 21 analysts polled by S&P Global, ACADIA Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $34. The average 1-year stock price forecast is 22.17% higher than the current stock price, while the lowest is $17 (-38.91%) and the highest is $49 (+76.07%).
Price Target: $34 (+22.17%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ACADIA Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 21 | 21 | 21 | 21 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $36 | Buy | Reiterates | $36 | +29.36% | Sep 3, 2026 |
| Deutsche Bank | Deutsche Bank | Buy Maintains $37 → $38 | Buy | Maintains | $37 → $38 | +36.54% | Aug 25, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $37 | Buy | Reiterates | $37 | +32.95% | Aug 25, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $36 | Buy | Maintains | $36 | +29.36% | Aug 25, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $27 → $28 | Hold | Reiterates | $27 → $28 | +0.61% | Aug 25, 2026 |
Financial Forecast
Revenue This Year
1.27B
from 1.07B
Increased by 18.77%
Revenue Next Year
1.43B
from 1.27B
Increased by 12.61%
EPS This Year
0.60
from 0.83
Decreased by -27.77%
EPS Next Year
0.89
from 0.60
Increased by 48.49%
EPS and Forward PE are based on non-GAAP adjusted numbers.